Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Regulus Therapeutics logo

About Regulus Therapeutics Stock (NASDAQ:RGLS)

Advanced Chart

Key Stats

Today's Range
$8.16
$8.16
50-Day Range
$7.87
$8.30
52-Week Range
$0.83
$8.35
Volume
N/A
Average Volume
1.02 million shs
Market Capitalization
$564.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Hold

Company Overview

Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Stock News Headlines

Novartis completes acquisition of Regulus Therapeutics
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Regulus Therapeutics Inc.
See More Headlines

RGLS Stock Analysis - Frequently Asked Questions

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14.

Regulus Therapeutics shares reverse split before market open on Wednesday, June 29th 2022.The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY).

Company Calendar

Last Earnings
5/08/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGLS
CIK
1505512
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$7.00
Potential Upside/Downside
+4.2%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46.36 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-57.53%
Return on Assets
-53.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.31
Quick Ratio
16.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.17 per share
Price / Book
6.97

Miscellaneous

Outstanding Shares
69,230,000
Free Float
66,222,000
Market Cap
$564.92 million
Optionable
Optionable
Beta
0.35

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:RGLS) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners